Avoro Capital Advisors Reduces $9M in Alkermes plc ($ALKS)

Avoro Capital Advisors has reduced its stake in Alkermes plc (NASDAQ: ALKS) by 200,000 shares, according to its latest Form 13F filing with the SEC. This move represents a 14.3% decrease, leaving Avoro with 1.2 million shares valued at approximately $54.2 million as of the filing date.

What Changed in Avoro Capital Advisors' Alkermes Position

Avoro Capital Advisors' recent filing shows a reduction of 200,000 shares in its Alkermes position, bringing its total holdings to 1.2 million shares. This represents a 14.3% decrease from the previous 1.4 million shares, with the current stake valued at about $54.2 million.

Other Institutional Activity in Alkermes

Several other institutional investors have also made changes to their positions in Alkermes. BlackRock, Inc. increased its holdings by 41,998 shares to a total of 28,314,410 shares, valued at approximately $1 billion. Baker Bros. Advisors LP maintained its position with 10,012,267 shares worth about $354 million. Vanguard Portfolio Management LLC now holds 9,511,112 shares, valued at roughly $336 million, after adding 9,511,112 shares. Meanwhile, State Street Corp reduced its stake by 7,572 shares, ending with 9,465,286 shares valued at around $335 million. Renaissance Technologies LLC decreased its holdings by 507,600 shares, leaving it with 6,160,428 shares valued at approximately $218 million.

Alkermes Stock Snapshot

Shares of Alkermes plc (NASDAQ: ALKS) are trading near $45.14. The company has a market capitalization of about $7.38 billion and a P/E ratio of 49.2. Alkermes' stock has a 52-week low of $25.17 and a high of $45.76, with a 50-day moving average of $37.02 and a 200-day moving average of $31.87. The company's current ratio is 2.27, with a quick ratio of 1.53 and a debt-to-equity ratio of 90.30.

Recent Earnings

In its most recent earnings report, Alkermes posted revenue of $1.56 billion, reflecting a growth of 28.2%. The company's earnings per share stood at $0.90, with a net margin of 9.8% and a return on equity of 9.4%. The next earnings release is scheduled for May 5, 2026.

Insider Buying and Selling at Alkermes plc

Recent insider transactions at Alkermes include planned sales by Christopher Wright of 2,000 shares on June 12, 2026, at an average price of $45.10. David Joseph Gaffin, EVP and CLO, sold 2,034 shares on June 4, 2026, at $43.05. Craig Hopkinson, EVP R&D and Chief Medical Officer, made several transactions on June 1, 2026, including a planned sale of 9,000 shares at $41.67 and a purchase of 5,000 shares at $19.34.

Analysts Set New Price Targets

Analysts remain optimistic about Alkermes, with several maintaining a 'buy' rating. On June 9, 2026, RBC Capital reiterated its 'buy' rating with a price target of $56. Baird and UBS both maintained their 'buy' ratings with a target of $48 on May 13 and May 6, respectively. The consensus among 16 analysts is a 'buy' rating with an average target price of $46.13.

About Alkermes

Alkermes plc is a biopharmaceutical company based in Dublin, Ireland. It focuses on developing and commercializing pharmaceutical products for treating opioid and alcohol dependence, schizophrenia, and bipolar I disorder. Alkermes also has a pipeline for neurological disorders and collaborates with companies like Janssen Pharmaceutica. The company was founded in 1987, employs about 2,050 people, and is led by CEO Richard F. Pops.

Bottom Line

Avoro Capital Advisors' reduction in its Alkermes stake is a notable change, reflecting a 14.3% decrease in holdings. Investors often track such filings to gauge institutional sentiment, though these 13F filings are backward-looking and may not represent current positions. With a strong market position and positive analyst ratings, Alkermes remains a company of interest in the healthcare sector.